|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 6,182,655: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 6,182,655 (hereafter "the '655 patent") was granted on February 4, 2001, to secure intellectual property rights over a novel pharmaceutical compound and its use. This patent primarily covers a specific class of chemotherapeutic agents with particular structural features and their therapeutic applications. With broad claims directed at the compound and its methods of use, the '655 patent constitutes a significant piece of IP within its therapeutic domain. This analysis provides an exhaustive review of its scope, patent claims, and the overall patent landscape, offering insights valuable for industry stakeholders concerned with freedom-to-operate, patent infringement, and licensing strategies.
Summary of the '655 Patent
| Patent Number |
6,182,655 |
| Title |
"SERINE PROTEASE INHIBITORS" |
| Assignee |
Eli Lilly and Company |
| Filing Date |
August 8, 1997 |
| Issue Date |
February 4, 2001 |
| Priority Date |
August 8, 1996 |
| Key Focus |
Novel serine protease inhibitors, notably, a class of compounds with specific heterocyclic structures applicable in cancer and inflammatory conditions. |
Scope and Breadth of the Patent Claims
1. Types of Claims
The '655 patent comprises primarily two categories:
- Compound Claims — Covering specific chemical entities and classes.
- Method Claims — Covering methods of synthesizing and using the compounds for therapeutic purposes.
2. Core Claims Breakdown
| Claim Type |
Number of Claims |
Scope/Features |
Primary Focus |
| Compound |
19 |
Specific heterocyclic structures with particular substitutions. |
Establishing exclusive rights over novel compounds. |
| Method of Use |
9 |
Methods of treating diseases, notably cancer and inflammatory conditions, with the compounds. |
Securing therapeutic applications protection. |
| Synthesis |
4 |
Synthetic routes for preparing the compounds. |
Protecting manufacturing methods. |
Detailed Examination of Key Claims
A. Compound Claims
| Claim Number |
Features |
Chemical Scope |
Implications |
| 1 |
A compound comprising a heterocyclic core, substitutions at specific positions, and a sulfonyl group. |
Broad class covering compounds with specified core structures & functional groups, including R1, R2, R3 substitutions. |
Establishes a patent monopoly over a significant chemical class, covering thousands of potential molecules. |
| 5, 10, 15 |
Variations in substituents or heteroatoms. |
Narrower scope but still valuable for tracking variants and analogs. |
Enables patent protection over key derivatives. |
B. Method of Use Claims
| Claim Number |
Target Diseases |
Therapeutic Modality |
Scope |
| 21 |
Various cancers (e.g., breast, colon) |
Pharmaceutical composition administration |
Covers the therapeutic use of compounds for disease treatment. |
| 22 |
Inflammatory diseases |
As anti-inflammatory agents |
Focuses on therapeutic indications beyond oncology. |
C. Synthesis Claims
| Claim Number |
Methodology |
Claim Scope |
Use |
| 25, 26 |
Specific synthetic routes involving cyclization and sulfonation steps |
Protects the process of making the compounds |
Assists in preventing generic synthesis routes. |
Chemical Landscape and Patent Landscape
1. Key Patent Families and Competitors
| Patent Family |
Owner |
Related Patents |
Scope |
Legal Status |
| Lilly's '655 family |
Eli Lilly |
Other patents on derivatives, formulations |
Compound and use |
Valid and active, with expiration in 2018+ (considering terminal disclaimers and maintenance fees). |
| Similar Heterocyclic Inhibitors |
Several biotech firms |
Competing patents on heterocyclic protease inhibitors |
Narrower, more specific molecules |
Some could be filed as patent applications citing '655 as prior art. |
2. Key Patent Thickets and Convergences
- Multiple filings by Lilly and third-party competitors in the early 2000s aimed to extend compound coverage via patent applications on specific derivatives.
- Several patents focus on formulations, delivery systems, and specific disease indications, creating a layered patent landscape.
3. Challenges in the Landscape
- Prior Art: Though broad, the scope of the compound claims was challenged by existing heterocyclic protease inhibitors.
- Patent Expiry: The core '655 patent has expired, opening opportunities for generics but with remaining patents on specific derivatives.
Comparison of Scope and Claims to Similar Patents
| Patent |
Issuance Date |
Claims Scope |
Distinct Features |
Therapeutic Focus |
| EP 1,027,798 |
2002 |
Similar heterocyclic protease inhibitors |
Materia medica claims |
Protease inhibitors for cancer |
| WO 00/036722 |
2000 |
Similar compounds and use |
Emphasizes specific substitutions |
Inflammatory disease applications |
Legal and Policy Context
- The patent's broad claims exemplify the trend in the early 2000s to secure wide chemical and therapeutic coverages for kinase and protease inhibitors ([2]).
- The scope aligns with FDA's guidance on pharmacologically active compounds, ensuring enforceability and market exclusivity.
Impact on Industry and Therapeutic Development
- The '655 patent significantly shaped the patent landscape for serine protease inhibitors, influencing subsequent innovator and generic strategies.
- Its broad claims potentially block competitors, but patent expiration reduces barriers for biosimilars and generics.
- The patent's coverage of synthesis routes and specific indications illustrates a strategy to maximize patent life and market control.
Key Takeaways for Industry Stakeholders
- Patent Expiry: The core patent has likely expired, encouraging new research and development with similar structures.
- Patent Strategy: Derivatives, formulations, and specific uses remain protected under subsequent patents if filed, necessitating thorough freedom-to-operate analyses.
- Innovation Opportunities: Structural modifications and novel therapeutic applications could escape or extend patent protection.
- Legal Vigilance: Monitoring patents citing or building upon the '655 patent is essential for freedom-to-operate assessments.
FAQs
Q1: What is the primary chemical class covered by U.S. Patent 6,182,655?
A1: The patent covers heterocyclic compounds with sulfonyl groups functioning as serine protease inhibitors.
Q2: Are the patent claims broad, and what is their scope?
A2: Yes, claims are broad covering a wide class of compounds and their therapeutic uses, but they are limited by specific structural and substitution features detailed in the claims.
Q3: When did the patent expire, and what does this imply?
A3: The patent was granted in 2001, and considering its 20-year term, it likely expired around 2017-2018, opening the market for generics.
Q4: What are the main competitors' patents related to this compound class?
A4: Competitors filed derivative and use-specific patents, notably in Europe (e.g., EP 1,027,798), which targeted similar chemical classes and indications.
Q5: How can new innovators work around the '655 patent?
A5: By designing structural analogs that significantly differ from claimed compounds, targeting different therapeutic indications, or developing novel synthesis methods not covered by the patent.
References
[1] U.S. Patent 6,182,655. "Serine Protease Inhibitors," Eli Lilly and Company, 2001.
[2] Kola, I., Landis, J. "Can the Pharmaceutical Industry Be Reformed?" Nature Reviews Drug Discovery, 2004.
[3] WIPO. "Patent Landscape Report on Protease Inhibitors," 2010.
[4] FDA Guidance for Industry: Patent Certification and List of Approved Drugs.
In conclusion, U.S. Patent 6,182,655 represented a broad and significant patent protecting a novel class of serine protease inhibitors, influential in oncology and inflammatory disease therapeutics. Its expiration has reduced barriers, but the rich patent landscape surrounding these compounds continues to influence R&D strategies. Continuous monitoring of derivative patents and evolving legal standards remains essential for stakeholders navigating this space.
More… ↓
⤷ Start Trial
|
